{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"previously untreated intermediate/poor-risk advanced renal cell carcinoma","name":"CA209-8Y8","nct_id":"NCT03873402","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ca209-8y8-nct03873402. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Nivolumab + ipilimumab","type":"EXPERIMENTAL"},{"description":null,"label":"Nivolumab + ipilimumab placebo","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-03-11","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":437,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":["Opdivo"],"type":"BIOLOGICAL"},{"name":"Ipilimumab","otherNames":["Yervoy"],"type":"BIOLOGICAL"},{"name":"Ipilimumab placebo","otherNames":[],"type":"OTHER"}],"last_update":"2026-01-21","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-03-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS) by blinded independent central review (BICR)","timeFrame":"Up to 34 months"},{"measure":"Objective response rate (ORR) by BICR","timeFrame":"Up to 23 months"}],"references":[],"start_date":{"date":"2019-06-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","url":"https://clinicaltrials.gov/study/NCT03873402"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ca209-8y8-nct03873402"}